posted on 2021-10-07, 16:13authored byRyan P. Ceddia, Dianxin Liu, Fubiao Shi, Mark K. Crowder, Sumita Mishra, David A. Kass, Sheila Collins
Cyclic nucleotides, cAMP and cGMP, are important second messengers for
the regulation of adaptive thermogenesis. Their levels are controlled not only
by their synthesis but also their degradation. Since pharmacological inhibitors
of cGMP-specific phosphodiesterase 9 (PDE9) can increase PKG signaling and UCP1
expression in adipocytes, we sought to elucidate the role of PDE9 on energy
balance and glucose homeostasis in vivo. Mice with targeted disruption
of the PDE9 gene, Pde9a, were fed nutrient matched high-fat (HFD) or
low-fat diets (LFD). Pde9a‑/‑
mice were resistant to HFD induced obesity, exhibiting a global increase in
energy expenditure, while brown adipose tissue (AT) had increased respiratory
capacity and elevated expression of Ucp1 and other thermogenic genes. Reduced
adiposity of HFD-fed Pde9a‑/‑ mice was associated with
improvements in glucose handling and hepatic steatosis. Cold exposure or treatment with β-adrenergic receptor agonists markedly decreased Pde9a
expression in brown AT and cultured brown adipocytes, while Pde9a‑/‑
mice exhibited a greater increase in AT browning; together suggesting that the PDE9-cGMP
pathway augments classical cold-induced β-adrenergic/cAMP AT browning and
energy expenditure. These findings suggest PDE9 is a previously unrecognized
regulator of energy metabolism and that its inhibition may be a valuable avenue
to explore for combating metabolic disease.
Funding
This work was supported by National Institutes of Health Grants R01 DK103056 (SC) and NIH R35-HL135827 (DAK), and AHA 16SFRN28620000 (DAK, SC).